ArticleGland surgery2020
Not all adrenal incidentalomas require biochemical testing to exclude pheochromocytoma: Mayo clinic experience and a meta-analysis.
Article in Gland surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Fat matters: practical imaging approach to microscopic and macroscopic fat in adrenal nodules.Abdominal radiology (New York) · 2026Review
- An interpretable machine learning framework using multi-phase computed tomography for differentiation of adrenal lipid-poor adenomas and pheochromocytomas.Frontiers in artificial intelligence · 2026Article
- A Rare Case of Metastatic Adrenal Melanoma.Cureus · 2024Article
- Imaging of Pheochromocytomas and Paragangliomas.Endocrine reviews · 2024Review
- A Laboratory Medicine Perspective on the Investigation of Phaeochromocytoma and Paraganglioma.Diagnostics (Basel, Switzerland) · 2023Review
- Article
- Rates of Pheochromocytoma/Paraganglioma Screening in At-Risk Populations.The Journal of clinical endocrinology and metabolism · 2023Article
- Canadian Urological Association guideline: Diagnosis, management, and followup of the incidentally discovered adrenal mass.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Article
- Predictive model of pheochromocytoma based on the imaging features of the adrenal tumours.Scientific reports · 2022Article
- Review
- Review
- Risk prediction model establishment with tri-phasic CT image features for differential diagnosis of adrenal pheochromocytomas and lipid-poor adenomas: Grouping method.Frontiers in endocrinology · 2022Article
- Approach to the Patient With Adrenal Incidentaloma.The Journal of clinical endocrinology and metabolism · 2021Review
- 2DWorld journal of gastrointestinal surgery · 2021Article
- Endocrine Causes of Hypertension.Current hypertension reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExcluding a pheochromocytoma is important when a patient presents with an incidentally discovered adrenal mass. However, biochemical testing for pheochromocytoma can be cumbersome, time consuming, or falsely positive. Our objective was to determine if unenhanced computed tomography (CT) imaging alone can be used to rule out pheochromocytoma.
methodsWe performed a retrospective study of all patients with a pathologically confirmed pheochromocytoma and unenhanced CT imaging who were treated at the Mayo Clinic between 1998 and 2016. Additionally, we performed a systematic review and meta-analysis of original studies published after 2005 with patients who had adrenal masses, more than 10 patients with pheochromocytomas, and reported attenuation on unenhanced CT imaging in Hounsfield units (HU).
resultsIn the Mayo cohort, we identified 186 patients and 199 pheochromocytomas with unenhanced CT imaging. The mean unenhanced CT attenuation was 35±9 HU (range, 15-62), and only 15 tumors had attenuation ≤20 HU. The systematic review identified 26 studies (1,217 tumors), and 23 studies provided a mean unenhanced CT attenuation. The overall mean unenhanced CT attenuation across the studies was 35.6 HU (95% CI, 22.0-49.1 HU). A cutoff of >10 HU had a 100% sensitivity (95% CI, 1.00-1.00) for pheochromocytoma with low heterogeneity between the 21 qualified studies (I
conclusionsBiochemical testing may not be required to exclude pheochromocytoma if an incidental adrenal mass has low attenuation (<10 HU) on unenhanced CT images.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.